Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content + • Associated with ulcerative colitis 40-60%, pancreatitis 12-25%, diabetes mellitus 5-10%, and rarely other autoimmune disorders• Onset during fourth or fifth decade of life• Increased risk for cholangiocarcinoma +++ Symptoms and Signs + • Intermittent jaundice• Fever• Right upper quadrant pain• Pruritus +++ Laboratory Findings + • Elevated alkaline phosphatase• Hyperbilirubinemia• Leukocytosis +++ Imaging Findings + • Right upper quadrant US, ERCP, and magnetic resonance cholangiopancreatography (MRCP) may show multiple dilatations and strictures of extrahepatic biliary ducts + • Cholangiocarcinoma• Presence of cirrhosis +++ Rule Out + • Cholangiocarcinoma + • History and physical exam• Liver function tests• Abdominal US• ERCP• Liver biopsy if question of cirrhosis• Brushings by percutaneous transhepatic cholangiography (PTC) or ERCP if question of malignancy +++ When to Admit + • Cholangitis +++ Surgery + • Balloon dilatation of multiple strictures• Resection of dominant stricture followed by biliary reconstruction• Liver transplantation (preferably before onset of cirrhosis) +++ Contraindications + • Cirrhosis +++ Medications + • Ursodiol (improves liver function and histology but no difference in 5-year clinical outcome) +++ Treatment Monitoring + • Alkaline phosphatase levels +++ Complications + • Cholangitis• Recurrent strictures• Primary nonfunction• Allograft rejection• Recurrent stricture post-transplant +++ Prognosis + • 85% survival rate 5 years post transplant• 71% actuarial survival at 5 years for resection of dominant stricture (only 20% if cirrhosis present)• 43% long-term success with balloon therapy for multiple strictures +++ References ++Kim WR et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75:688. [PubMed: 10907383] ++van Hoogstraten HJ et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol. 1998;29:417. ++Kubicka S et al: K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001;48:403. [PubMed: 11171833] ++Ryder SD, Beckingham IJ: ABC of diseases of liver, pancreas, and biliary system. Other causes of parenchymal liver disease. BMJ 2001;322:290. [PubMed: 11157536] Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.